While Encysive Pharmaceuticals Inc. received a third approvable letter for Thelin (sitaxsentan sodium) on Friday, Gilead Sciences Inc. got approval for Letairis (ambrisentan), a competing endothelin A receptor antagonist for pulmonary arterial hypertension (PAH). (See Encysive story this issue).(BioWorld Today)

Gilead Gets Letairis Approval, Potential Best In Class For PAH

June 19, 2007

By Trista Morrison

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...